Is Moderna Overdosing in the KidCove Clinical Trial?

Is Moderna Overdosing on the KidCove Clinical Trial?

The Moderna Kidcove trial tests the efficacy of the vaccines under Emergency Use Authorization (EUA) in children. As we already know, NCT04649151 was used to gain EUA for Moderna mRNA-1273 in children/adolescents 12 to 18 years of age. The dosing of this trial was the same as used in adults regardless of body weight. It was two (2) doses of 100mcg. We've already seen a strong correlation of myocarditis in the younger populations from the mRNA vaccines, which has led to warnings. While the warnings are for young males, myocarditis in young females is much higher than the expected occurrence rate in this age group. We have also seen that even a reduced dose of only 25% in adults has yielded strong immunogenicity. It's very concerning that lower dosages were not tested in this younger population. 

Unfortunately, the U.S. Food and Drug Administration (FDA) and Moderna haven't learned from their past. In the Kidcove RCT, they use 50mcg and 100mcg dosing for children between 2-12 years old. Shockingly, they are using 25mcg, 50mcg, and 100mcg in children under two. It's questionable if trials should be conducted on children under 12 years old, much less under two years. Then to t...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee